Immunotherapy of Cancer
- 1st Edition, Volume 143 - June 14, 2019
- Latest edition
- Editors: Xiang-Yang Wang, Paul B. Fisher
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 1 7 0 2 2 - 9
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 1 7 0 2 3 - 6
Immunotherapy of Cancer, Volume 143, the latest release in the Advances in Cancer Research series, provides invaluable information on the exciting and fast-moving field of cancer… Read more
Immunotherapy of Cancer, Volume 143, the latest release in the Advances in Cancer Research series, provides invaluable information on the exciting and fast-moving field of cancer research. Contributions from leading experts in the field make this a must have update on the topic.
- Provides that latest information on cancer research
- Offers outstanding and original reviews on a range of cancer research topics
- Serves as an indispensable reference for researchers and students alike
Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology
1. Translation of cancer immunotherapy from the bench to the bedsideQianyu Guo, Fan Huang, Christophe Goncalves, Sonia V. del Rincón and Wilson H. Miller, Jr.2. From immune checkpoints to vaccines: The past, present and future of immunotherapyArsen Osipov, Adrian Murphy and Lei Zheng3. Co-stimulatory and co-inhibitory pathways in cancer immunotherapy Rachel E. O’Neill and Xuefang Cao4. Immunometabolism: A new target for improving cancer immunotherapyChunqing Guo, Shixian Chen, Wenjie Liu, Yibao Ma, Juan Li, Paul B. Fisher, Xianjun Fang and Xiang-Yang Wang5. Impact of the microbiome on cancer progression and response to anti-cancer therapiesClaire Buchta Rosean, Tzu Yu Feng, Francesca N. Azar and Melanie R. Rutkowski6. Immunotherapy in breast cancer: Current status and future directionsAmrita Basu, Ganesan Ramamoorthi, Yongsheng Jia, Jon Faughn, Doris Wiener, Sabrina Awshah, Krithika Kodumudi and Brian Czerniecki7. Can CpG methylation serve as potential surrogate markers for immune infiltration in cancer?Manny D. Bacolod, Francis Barany and Paul B. Fisher
- Edition: 1
- Latest edition
- Volume: 143
- Published: June 14, 2019
- Language: English
XW
Xiang-Yang Wang
Professor, Dept of Human & Molecular Genetics, Virginia Commonwealth University, USA; Associate Director, VCU Institute of Molecular Medicine, Virginia, USA. The Wang laboratory has a long-standing interest in understanding stress response and stress sensing molecules in regulation of inflammation, host immunity, and the pathogenesis of diseases, including cancer.
Affiliations and expertise
Institute of Molecular Medicine, Virginia Commonwealth University, USAPF
Paul B. Fisher
Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).
Affiliations and expertise
Department of Human and Molecular Genetics, VCU Institute of Molecular Medicine, VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Virginia, USARead Immunotherapy of Cancer on ScienceDirect